{"id":"fid007","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Increased risk of genital mycotic infections"},{"rate":"5-10%","effect":"Increased risk of hypotension"},{"rate":"0.1-0.5%","effect":"Increased risk of euglycemic diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, FID007 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.","oneSentence":"FID007 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:05.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT06332092","phase":"PHASE2","title":"FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fulgent Pharma LLC.","startDate":"2024-04-10","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT06338657","phase":"PHASE1","title":"FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2024-04-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":1},{"nctId":"NCT03537690","phase":"PHASE1","title":"FID-007 in Treating Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2018-05-25","conditions":"Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Paclitaxel in Polyethyloxazoline Polymer; FID-007; FID007 (CN); FID 007; Nanoencapsulated Paclitaxel FID-007"],"phase":"phase_2","status":"active","brandName":"FID007","genericName":"FID007","companyName":"Fulgent Pharma LLC.","companyId":"fulgent-pharma-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FID007 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}